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ABSTRACT
Carbendazim, a widely used fungicide, exhibits reproductive and developmental toxicity. The objective of this study was to investigate the expression of androgen receptor induced by carbendazim and the antagonistic effect of flutamide. Rats were treated with carbendazim, flutamide or a combination of both to measure androgen receptor mRNA, immune activity and protein expression. Carbendazim
treatment increased androgen receptor mRNA in a dose-dependent manner, while flutamide, an androgen receptor antagonist, blocked
the androgen receptor mRNA. Co-treatment with carbendazim and various flutamide doses decreased the androgen receptor mRNA
in a dose-dependent manner. Conversely, co-treatment with flutamide and various carbendazim doses increased the androgen receptor
mRNA in a dose-dependent manner. Immunohistochemistry and Western blot analyses showed that carbendazim increased androgen
receptor activity (especially in rat testes) in a dose-dependent manner, while flutamide decreased it. Furthermore, carbendazim or
flutamide treatment for 7 days increased testosterone and follicular stimulating hormone concentrations in the serum of male rats in a
dose-dependent manner, which might involve the disruption of the androgen receptor. Although we need to examine the exact mechanism
of androgen receptor involved in the reproductive toxicity and endocrine-disrupting activity induced by carbendazim and its parent,
benomyl, we should first discuss how to take advantage of flutamide antagonism on carbendazim-induced reproductive and endocrinedisrupting activity possibly in human. In summary, carbendazim induced androgen receptor expression in mRNA and protein levels,
while flutamide antagonized this effect. This is the first report on the antagonistic effect of flutamide on the carbendazim-androgenic
effect on mRNA and protein levels. The results would help to clarify the mechanism of carbendazim- and chemical-induced developmental toxicity and endocrine-disrupting activity.
Key words: Carbendazim, Flutamide, endocrine-disrupting activity, androgen receptor, male rats

INTRODUCTION
Carbendazim (methyl-2-benzimidazole carbamate,
MBC) is a systemic fungicide used to kill pests(1). The LD50
of carbendazim and its precursor, benomyl, is above 10,000
mg/kg/day in rats, which makes it a low toxicity pesticide(2).
Previous studies show that carbendazim and benomyl
induce testicular atrophy and inhibit microtubule function(3),
leading atrophy of semiferous(4) and infertility(5). Carbendazim treatment induces embryolethality, craniomeningocele, exencephaly, microphthalmia and hydrocephalus(6).
* Author for correspondence. Tel: +886-4-23302101 ext. 505;
Fax: +886-4-23323073; E-mail: lusueyen@tactri.gov.tw

Benomyl treatment produces exencephaly, hydrocephalus
and cleft palate(7).
The abnormalities induced by carbendazim and
benomyl occur in male and female rats. Rehnberg et al.
reported that carbendazim treatment increases the level
of androgen-binding protein in the serum, interstitial fluid
and seminiferous tubule fluid in the testes(8). This implies
that the androgen receptor is involved in the carbendaziminduced abnormalities of reproductive tissues, such as the
testes in rats. Lim and Miller later reported that carbendazim treatment did not induce severe testicular toxicity
in male rats during pre-puberty, but did so during puberty
and post-puberty(3). This implies that androgen receptors
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are active during puberty and post-puberty, but not in prepuberty. The androgen receptor plays an important role
in the growth of uterus in rats(9,10). Carbendazim induces
endocrine-disrupting activity in the offspring of male and
female rats(11). Carbendazim and flutamide exposure in utero
has antagonistic and synergistic effects on reproductive and
developmental toxicity in rats(12). Yamada et al. indicated that
functional genomics may explain the inability of benomyl to
act via steroid-receptor-mediated mechanisms(13). Flutamide
and linuron anti-androgens decreased the androgen receptor
mRNA of rat testes. This decrease may be related to the antiandrogenic activity induced by flutamide and linuron(14,15).
The effects of carbendazim and its precursor benomyl
on mammals and birds include male reproductive toxicity,
developmental toxicity and endocrine-disrupting activity.
Previous reports indicate that carbendazim and benomyl
effects include sloughing of germ cells, testes and epididymis toxicity, and DNA damage of testicular cells(16-31). In
addition to male toxicity, carbendazim and benomyl induce
developmental toxicity in mammals, according to in vitro
and in vivo tests(7,11,12,32-41).
Relatively little information is available concerning the
endocrine-disrupting activity induced by carbendazim and
benomyl. Some reports show that carbendazim and benomyl
increase the serum and pituitary luteining hormone (LH),
17ß-estradiol (E2) and follicular stimulating hormone (FSH)
(6,42)
. However, the mechanism of reproductive and developmental toxicity remains unclear. Rajeswary et al. showed
that carbendazim-induced reproductive toxicity is due to
increasing oxidative stress(43). Spencer et al. indicated that
carbendazim and benomyl led to developmental toxicity and
that it is unrelated to steroid or receptor mechanisms(36).
Previous research also shows that carbendazim and colchicine are both microtubule disruptors in rats. Markelewicz Jr.
et al. indicated that carbendazim and 2,5-hexanedione synergistically disrupt rat spermatogenesis due to their effects
on microtubules(44). The molecular mechanism of carbendazim’s endocrine-disrupting activity remains unclear.
This study investigated whether the carbendazim-induced
androgen receptor expression is antagonized by flutamide in
the testes, epididymis and prostate of rats. This study hypothesized that carbendazim could induce androgen receptor
expression in the testes, epididymis and prostate of male rats.
Further, the carbendazim-induced androgen receptor expression in the testes, epididymis and prostate could be reversed
by the anti-androgen, flutamide. To test the hypotheses, rats
were exposed to carbendazim and flutamide separately and
in combination.

MATERIALS AND METHODS
I. Animals and Treatments
Three-week-old male Sprague-Dawley rats were
purchased from the National Laboratory Animal Center,
Taipei, Taiwan. The rats were housed in a specific-pathogen-

free animal facility in the Taiwan Agricultural Chemicals
and Toxic Substances Research Institute (TACTRI) in Taichung. The animal rooms were maintained at a 12-hour light
and dark cycle, 23 ± 2°C and 50 ± 10% relative humidity.
Upon arrival, the rats were quarantined for at least 1 week and
were released only when they exhibited adequate body weight
gain and no clinical signs of disease or injury. Carbendazim
(99% pure) was obtained from Sinon Co. (Taichung, Taiwan).
Flutamide (FLU) and the other chemicals were obtained from
Sigma (St. Louis, MO, USA), unless otherwise stated. The
pesticide was suspended in corn oil and orally administered
to five rats in each group once a day by gavage at a volume of
2.5 mL/kg body weight. Male rats (322 ± 15 g) were randomly
assigned to each treatment group. In order to carry out the
time- and dose-dependent tests, the protocol included two
treatment-duration and dosages. The first one was as follows:
The doses of carbendazim were 0, 25, 50, 100, 200, 400 and
800 mg/kg/day for 56 days. The doses of flutamide were
0, 6.25, 12.5, 25, 50 and 100 mg/kg/day for 28 days. In mixed
doses, the rats were co-treated with 675 mg/kg/day of carbendazim and 0, 6.25, 12.5, 25, 50 and 100 mg/kg/day of flutamide for 28 days. The second one was as follows: The doses
of carbendazim were 0, 6.25, 25, 100 and 400 mg/kg/day for 7
days, while the doses of flutamide were 0, 0.78, 3.13, 12.5 and
50 mg/kg/day for 7 days. The rats in the co-treatment group
were given either 400 mg/kg of carbendazim and 0, 0.78,
3.13, 12.5 and 50 mg/kg/day of flutamide, or 50 mg/kg/day
of flutamide and 0, 6.25, 25, 100 and 400 mg/kg/day of
carbendazim for 7 days. All animal care and experimental
procedures were approved by the Committee for Animal
Experiment Management of TCATRI.
II. Immunohistochemical (IHC) Evaluation
The testes tissues of three groups of rats were tested:
1) 0, 25, 50, 100, 200, 400 and 800 mg/kg/day of carbendazim
for 56 days; 2) 0, 6.25, 12.5, 25, 50 and 100 mg/kg/day of flutamide for 28 days; and 3) co-treatment with 675 mg/kg/day
of carbendazim and 0, 6.25, 12.5, 25, 50 and 100 mg/kg/day
of flutamide for 28 days. Testes from the following test
groups were fixed in 10% neutral buffered formalin for one
week. The tissues were then dehydrated with increasing
concentrations of ethanol, cleared in toluene and embedded
in paraffin. Sections were cut into 5-mm slices and deparaffinized, hydrated and treated with 0.3% H2O2 in PBS
(pH 7.6) for 30 min to block endogenous peroxidase activity,
and finally treated with a protein-blocking solution (5% goat
serum diluted in phosphate-buffered saline). These steps
were followed by heating the sections in a microwave oven
for antigen retrieval using a 0.01 M citrate buffer solution
(pH 5.5). Tissue sections were immunostained with rabbit
anti-AR (N-20, Santa Cruz Biotechnology, Inc., CA, USA),
which was diluted 1 : 250 in phosphate-buffered saline
and 0.25% bovine serum albumin and maintained at room
temperature overnight. The tissue sections were then developed with a streptavidin-HRP kit (Chemicon IHC Select®
CA, USA), using diaminobenzidine as the chromogen, and
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were counterstained with hematoxylin. All images were
optimized by using a inverted microscope (Leica, Wetzlar
GmbH, Germany). To quantify the relative amount of AR
protein in the IHC, 200 nucleus stained per field in a slide, 5
field per slide, 5 slides per dose were counted. The intensity
of AR protein stained in nucleus was graded as (0, negative),
+ (1, mild), ++ (2, moderate), +++ (3, intense), ++++ (4,
more intense) or +++++ (5, very intense). The measurements
were control group adjusted and the values were statistically
analyzed.
III. Reverse Transcription-Polymerase Chain Reaction
(PCR)
Testes (n = 5) from the following treatment groups
were stored at -80°C for 7 days. Total RNA was extracted
with an RNeasy® Mini kit (QIAGEN, TAIGEN Bioscience Corporation, Duesseldorf, Germany) according to the
protocol provided by the manufacturer. For the reverse transcription (RT) reaction, 3 mL of total RNA was used from
the individual rats of each group. The RT-PCR reactions in
this study were carried out with SuperScriptTM III One-Step
RT-PCR System with Platinum® Taq DNA polymerase kits
from Invitrogen (Cat. No. 12574-026) in DNA Engine® &
DNA Engine Tetrad® Peltier Thermal Cyclers (PTC-200,
MJ Research, Incorporated, Massachusetts 02451 USA).
For AR mRNA amplification, the primers were designed to
amplify a 570-bp fragment (forward, 5'-TGCTGCCTTGTTATCTAGTCTCA-3'; reverse, 5'-ACCATATGGGACTTGATTAGCAG-3') (annealing temperature, 60°C; the
number of cycles, 24, 26 and 28; product size, 570 bp). PCR
was subsequently performed using an optimized protocol
of between 24 and 28 cycles. Each cycle consisted of
the following: 94°C, 30 s; 60°C, 30 s and 72°C, 45 s. For
b-actin mRNA amplification, the primers were designed
to a 359-bp fragment (forward, 5'-CTGTGCCCATCTATGAGGGTTAC-3'; reverse, 5'-AATCCACACAGAGTACTTGCGCT-3') (annealing temperature, 60°C; the number of
cycles, 24, 26 and 28; product size, 359 bp). PCR was subsequently performed using an optimized protocol of between
24 and 28 cycles. Each cycle consisted of the following: 94°C,
30 s; 60°C, 30 s and 72°C, 45 s. PCR products were resolved
in a 1.2% agarose gel and stained with ethidium bromide, and
DNA bands from triplicate reactions were quantified using
a FOTO/Analyst® Investigator System (Fotodyne Incorporated, Hartland, WI, USA). The PCR products for β-actin
served as an internal standard.
IV. Western Blot
A Polytron PT3100 homogenizer (Kinematica AG,
Littau, Switzerland) was used to examine frozen testicular
tissues from the following treatment groups. Tissues of testes
from the first protocol were homogenized for a few seconds
in an M-PER® Mammalian Protein Extraction Reagent (Cat.
No. 78505, Pierce). The homogenates were then centrifuged
at 105,000 ×g for 1 h at 4°C. The supernatants were aliquoted

and stored at -86°C before use. Before western blotting,
protein contents were measured by BCA protein assay (Cat.
No. 23225, Pierce) with BSA as the standard. Equal amounts
of protein were loaded onto each polyacrylamide gel. The
antibody dilutions were 1 : 200 for the anti-AR antibody
(N-20, Santa Cruz Co., CA) and 1 : 5000 for the horseradish
peroxidase conjugated goat anti-rabbit IgG (AP132P, Chemicon International).
For each treatment group, five samples were analyzed in
two separate blots. Total protein extracts from the testicular
tissue were denatured and separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
with 7.5% polyacrylamide. The proteins were transferred
to nitrocellulose membranes. The membranes were then
blocked for non-specific binding and incubated with polyclonal primary antibodies for AR (N-20, Santa Cruz Co., CA)
and β-actin (AP132P, Chemicon International). After incubation with primary antibody, the membranes were incubated
with horseradish peroxidase-linked anti-goat IgG secondary
antibody and visualized on film exposed to enhanced chemiluminescence (VisualizerTM Western Blot Detection Kit,
Millipore, MA, USA). The relative amount of protein in the
resulting immunoblot bands was estimated by measuring the
optical densities of the bands on exposed films using a FOTO/
Analyst® Investigator System (Fotodyne Incorporated, WI,
USA). The measurements were background adjusted and the
values were statistically analyzed. Protein for ß-actin served
as an internal standard.
V. Hormone Analysis
Serum luteinizing hormone (LH) (RPN 2562, Amersham, UK), follicular stimulating hormone (FSH) (RPN 2560,
Amersham, UK; AE R004, Biocode, Belgium), 17b-estradiol
(E2) (Cayman Chemical., Ann Arbor, MI, USA) and testosterone (T) (Cayman Chemical., Ann Arbor, MI, USA) levels
were determined using the relevant EIA systems. The serum
samples collected from rats treated with 0, 6.25, 25, 100 and
400 mg/kg/day of carbendazim for 7 days and 0, 0.78, 3.13,
12.5 and 50 mg/kg/day of flutamide for 7 days were directly
applied to the well in the kit and measurements were taken
according to the procedure described by the manufacturer.
VI. Statistical Analysis
The values of AR in Western blot and RT-PCR were
normalized against b-actin. All results were statistically
analyzed with the t-test and p < 0.05 was considered statistically significant. The other data were expressed as mean ±
SE. Data were subjected to ANOVA followed by t-test. The
level of significance was set at p < 0.05.

RESULTS
I. Effects of Carbendazim, Flutamide and Combined
Treatment on Androgen Receptor Immunolabeling
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The testes of rats treated with 25, 50, 100, 200, 400 and
800 mg/kg/day of carbendazim for 56 days exhibited significantly increased androgen receptor immunoexpression in a
dose-dependent manner (Figure 1). However, treatment with
6.25, 12.5, 25, 50 and 100 mg/kg/day of flutamide for 28 days
significantly decreased androgen receptor immunoexpression in a dose-dependent manner when compared to that of
control (data not shwon). Co-treatment with 675 mg/kg/day of
carbendazim and 6.25, 12.5, 25, 50 and 100 mg/kg/day of

Figure 1. Effects of MBC treatment on AR activity using IHC in rat
testes. Male Sprague-Dawley rats were treated orally with MBC once
daily for 56 days, Control rats were treated with corn oil only. Immunohistochemical staining of AR activity was evaluated based on the
degree of staining, as described in the Materials and Methods section.
Each value indicates the mean ± SD for five rats. The * values are
significantly different from the control value, p < 0.05. Values in the
bar chart followed by the same letter are not significantly different
according to the t-test of 0.05 level. Magnification, 400×.

flutamide for 28 days significantly decreased androgen
receptor immunoexpression when compared to that of
carbendazim alone (data not shwon). A comparison of
the androgen receptor immunoexpression induced by
carbendazim, flutamide and their combination shows that
675 mg/kg/day carbendazim could reverse the effect of a
gradually increasing dose of flutamide until 100 mg/kg/day.
This shows that flutamide had a stronger antagonist effect
than carbendazim. In addition to measuring the testis tissue,
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Figure 2. Effects of MBC treatment on AR activity using IHC in rat testes. Male Sprague-Dawley rats were treated orally with MBC at the
doses indicated once daily for 7 days. Control rats were treated with corn oil only. Immunohistochemical staining of AR activity was evaluated
based on the degree of staining, as described in the Materials and Methods section. Each value indicates the mean ± SD for five male rats. The *
values are significantly different from the control value, p < 0.05. Values in bar chart followed by the same letter are not significantly different
according to the t-test of 0.05 level.

we also investigated the effect of carbendazim, flutamide
and in combination on tissues of epididymis and prostate
in male rats. Basically carbendazim induced the androgen
receptor protein in epididymis and prostate but there is no
dose-dependent manner when compared to that of control
group (data not shwon). Treatment with 6.25, 12.5, 25, 50
and 100 mg/kg/day of flutamide for 28 days significantly
decreased the androgen receptor protein expression in epididymis without dose-dependent manner and in prostate with
dose-depdenent manner when compared to that of control
group (data not shwon). Co-treatment with 675 mg/kg/day
of carbendazim and 6.25, 12.5, and 50 mg/kg/day of flutamide for 28 days significantly decreased androgen receptor
protein in epididymis but not in 25 and 100 mg/kg/day flutamide when compared to that of carbendazim alone (data not
shwon). Also, co-treatment with 675 mg/kg/day of carbendazim and 6.25, 12.5, 25, 50 and 100 mg/kg/day of flutamide
for 28 days significantly decreased androgen receptor protein

in prostate when compared to that of carbendazim alone (data
not shwon).
To further determine the dose- and time-dependent
effects of carbendazim, flutamide and their combination on
androgen receptor immunoexpression in rat testes, the doses
and treatment period were shortened. Treatment with 6.25,
25, 100 and 400 mg/kg/day of carbendazim for 7 days significantly induced the androgen receptor immunoexpression in
a dose-dependent manner in rat testes (Figure 2). However,
treatment with 0.78125, 3.125, 12.5 and 50 mg/kg/day of
flutamide for 7 days significantly decreased the androgen
receptor immunoexpression in rat testes (data not shwon),
which is likely because flutamide reduced androgen receptor
mRNA in androgen receptor activity. Co-treatment with
400 mg/kg of carbendazim and 0.78125, 3.125, 12.5 and
50 mg/kg/day of flutamide significantly decreased androgen
receptor immunoexpression in a flutamide dose-dependent
manner in rat testes (data not shwon). However, co-treatment
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with 50 mg/kg/day of flutamide and 6.25, 25, 100 and
400 mg/kg/day of carbendazim significantly increased the
androgen receptor immunoexpression in a carbendazim
dose-dependent manner in rat testes (data not shown).
II. Effects of Carbendazim, Flutamide and Their Combination on Androgen Receptor mRNA Expression in Male Rats
Treatment with 6.25, 25, 100 and 400 mg/kg/day of
carbendazim for 7 days significantly increased androgen
receptor mRNA expression in a dose-dependent manner
in rat testes. However, the androgen receptor expression
induced by 400 mg/kg/day of carbendazim was less than
that induced by a dose of 100 mg/kg/day (Figure 3A). This
suggests that carbendazim is an androgen receptor agonist in
rat testes. In contrast, treatment with 0.78125, 3.125, 12.5 and
50 mg/kg/day of flutamide for 7 days significantly decreased

(A)

androgen receptor expression in a dose-dependent manner
in rat testes (Figure 3B). As flutamide is a well-known
androgen receptor antagonist, this result confirmed previous
results and could be used as a quality control(14). Co-treatment with 400 mg/kg of carbendazim and 0.78125, 3.125,
12.5 and 50 mg/kg/day of flutamide significantly decreased
androgen receptor mRNA in a flutamide dose-dependent
manner (Figure 3C). This suggests that flutamide antagonized carbendazim-induced androgen receptor expression.
Inversely, co-treatment with 50 mg/kg of flutamide and 6.25,
25, 100 and 400 mg/kg/day of carbendazim significantly
increased the androgen receptor mRNA in a carbendazim
dose-dependent manner (data not shown). This suggests that
a high dose of carbendazim can have an agonistic effect on
the androgen receptor expression by competing with flutamide to bind to the androgen receptor.
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Figure 3. Effects of treatment with (A) MBC, (B) FLU or (C) fixed
MBC and varying dose of FLU on mRNA expression of AR in rat
testes as analyzed by RT-PCR. Male Sprague-Dawley rats were
administered orally with MBC at the doses indicated once daily for 7
days. Control rats were treated with corn oil only. This figure shows
images of agarose gel electrophoresis of PCR products. The relative
amount of AR to β-actin mRNA was determined by the intensity of
the ethidium bromide. Each value indicates the mean ± SD for five
male rats. The * values are significantly different from the control
value, p < 0.05. The † values are significantly different from the MBC
control value, p < 0.05. Values in bar chart followed by the same letter
are not significantly different according to the t-test of 0.05 level.

424
Journal of Food and Drug Analysis, Vol. 19, No. 4, 2011

III. Effects of Carbendazim, Flutamide and Their Combination on Androgen Receptor Protein Expression
In addition to investigating the androgen receptor
mRNA and immunoexpression, this study further analyzes
the androgen receptor protein expression induced by carbendazim, flutamide and their combination. Treatment with 25,
50, 100, 200, 400 and 800 mg/kg/day of carbendazim for
56 days significantly increased androgen receptor protein
in a dose-dependent manner (Figure 4A), except for the
dose of 400 mg/kg/day (data not shown). At doses of 6.25,
25, 100 and 400 mg/kg/day of carbendazim for 7 days, 400
mg/kg of carbendazim showed no androgen receptor protein
expression. Immunohistochemistry analysis shows that
this may be due to the death of Sertoli cells. Basically, this
result agrees with the androgen receptor protein (Figure 1).
However, treatment with 6.25, 12.5, 25, 50 and 100 mg/kg/

day of flutamide for 28 days significantly decreased androgen
receptor immunoexpression in a dose-dependent manner
(Figure 4B). Co-treatment with 675 mg/kg of carbendazim
and 6.25, 12.5, 25, 50 and 100 mg/kg/day of flutamide for
28 days significantly decreased androgen receptor protein in
a flutamide dose-dependent manner, except for the dose of
6.25 mg/kg/day (Figure 4C). A comparison of the androgen
receptor protein expression induced by carbendazim, flutamide and their combination shows that carbendazim could
reverse the flutamide effect in rat testes.
To further study the dose- and time-dependent effects of
carbendazim, flutamide and their combination on androgen
receptor protein expression in rat testis, the doses and treatment period were shortened. Treatment with 6.25, 25, 100
and 400 mg/kg/day of carbendazim for 7 days significantly
increased androgen receptor protein expression in rat testes
in a dose-dependent manner, except for the 400 mg/kg/day
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Figure 4. Effects of MBC treatment on AR protein expression using
Western blotting analysis in rat testes. Male Sprague-Dawley rats
were treated orally with (A) MBC once daily for 56 days, or (B) FLU
once daily for 28 days, or (C) co-treated orally with MBC and FLU
once daily for 28 days. Control rats were treated with corn oil only.
The Western blot of AR was evaluated as described in the Materials
and Methods section. Each value indicates the mean ± SD for five rats.
The intensity of the AR bands was measured by densitometric scanning. The AR protein was normalized to the intensities of β-actin and
one result of five replicate experiments is shown here. The * values are
significantly different from the control value, p < 0.05. The † values
are significantly different from the MBC control value, p < 0.05.
Values in bar chart followed by the same letter are not significantly
different according to the t-test of 0.05 level.
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dose (data not shown). Treatment with 400 mg/kg/day of
carbendazim showed no androgen receptor protein expression, which may be due to the death of Sertoli cells in the
testes. However, treatment with 0.78125, 3.125, 12.5 and 50
mg/kg/day of flutamide for 7 days significantly decreased
the androgen receptor protein expression in rat testes (data
not shwon). This result agrees with the androgen receptor
mRNA and immunohistochemistry analysis.

DISCUSSION

Treatment with carbendazim or flutamide for 7 days
increased the testosterone concentration in the serum of male
rats in a dose-dependent manner (Figure 5A and 5B). Treatment with carbendazim or flutamide for 7 days increased the
follicular stimulating hormone concentration in the serum of
male rats in a dose-dependent manner (Figures 5C and 5D).

The results of this study show that exposure to carbendazim for 7 and 56 days induced androgen receptor gene
expression in a dose-dependent manner in rat testes. The
following pieces of evidence indicate carbendazim-induced
androgen receptor gene expression. Firstly, carbendazim
increased androgen receptor mRNA, immune activity and
protein expression in a dose-dependent manner and was
antagonized by flutamide. Secondly, carbendazim induced
androgen receptor immune activity and protein expression
in a time-dependent manner. Thirdly, carbendazim induced
androgen receptor mRNA, immune activity and protein
expression in the testes, epididymis and prostate in a dosedependent manner.
The results of androgen receptor protein expression in
400 mg/kg of carbendazim for 7 days and 56 days showed
unreasonable but consistent data. This may be because
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Figure 5. Effects of treatment with (A) MBC and (B) FLU on serum testosterone or (C) MBC and (D) FLU on serum FSH level in male rats.
Male Sprague-Dawley rats were treated orally with MBC or FLU once daily for 7 days. Control rats were treated with corn oil only. Serum
testosterone was evaluated as described in the Materials and Methods section. Each value indicates the mean ± SD for five rats. The * values are
significantly different from the control value, p < 0.05. Values in bar chart followed by the same letter are not significantly different according to
the t-test of 0.05 level.
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the damage in the Sertoli cells of the testes led to a loss of
androgen receptor protein expression. Reproductive and
developmental toxicity exhibits drug specific, phase specific
and dose specific characteristics. It is quite possible that a
dose of 400 mg/kg of carbendazim damaged the Sertoli cells
in the testes of rats with dose-specific activity and futher
investigation is required. The other unreasonable data is that
the co-treatment with 675 mg/kg/day of carbendazim and
6.25 mg/kg/day of flutamide decreased androgen receptor
protein levels more than the treatment with 675 mg/kg/day
of carbendazim alone. Whether the analysis process resulted
in the effect or unrecovered implications still needs to be
investigated.
This is the first study to show that carbendazim induced
androgen receptor mRNA, immunoexpression and protein
expression in rats. This result might explain the endocrine-disrupting activity in carbendazim-, flutamide- and
co-treatment-induced and antagonized reproductive and
developmental toxicity in rats. The endocrine-disrupting
activities were as follows: Co-treatment of male rats with
675 mg/kg/day of carbendazim and 50 or 100 mg/kg/day
of flutamide once daily for 28 days blocked the decrease in
testicular weight induced by treatment with carbendazim
alone(11). Co-treatment prevented the loss of spermatozoa
and cell morphology and the decrease in sperm concentration induced by carbendazim. We have proved that endocrine-disrupting activity in carbendazim-induced reproductive and developmental toxicity in rats(11). Also we reported
that antagonistic and synergistic effects of carbendazim and
flutamide exposures in utero on reproductive and developmental toxicity in rats(12). We inferred that AR might play
an important role in carbendazim-induced reproductive and
developmental toxicity and endocrine-disrupting activity.
This topic requires further investigation.
The carbendazim-induced androgen receptor expression in rat testes is in marked contrast to that induced by
anti-androgens. Most androgen receptor disruptors are
anti-androgens, including vinclozolin, prochloraz, di(2ethylhexyl)phthalate (DEHP), finasteride, linuron, p,p’-DDT
and -DDE, and iprodione(45-48). The significant difference
between these disruptors is that AR is an agonist for carbendazim and an antagonist for those anti-androgens. Though
damage such as testicular atrophy in the reproductive tissues
of male rats seems to be common and similar in pathology
between carbendazim and anti-androgens, the mechanism of
toxicity may be quite different and requires further analysis.
The current study shows that the androgen receptor
expression in the reproductive tissues of rats can be antagonized by flutamide in a dose- and time-dependent manner.
Whether androgen receptor plays an important role in
carbendazim-induced reproductive and developmental
toxicity and endocrine-disrupting activity and how it acts in
these toxicities requires further clarification.
Based on chemical structures and reproductive toxicity
and endocrine-disrupting activity induced by flutmaide and
carbendazim, we speculated that the principle of flutamide
antagonistic on carbendazim-induced reproductive toxicity

and endocrine-disrupting activity is androgen receptor
affinity of the functional groups NCO and NOO, while that
of carbendazim, androgen receptor agonist, is androgen
receptor affinity of the functional group, NCOO and C and
D ring of testosterone. The androgen receptor antagonistic
pesticides, vinclozolin(49-55), procymidone(56-57), linuron(58)
and iprodione(56) also shared the same functional groups
NCO and NCN of androgen receptor affinity.
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